Data for Lipidomics in (SIDS) Sudden Infant Death Syndrome (Study ST000673)

(Analysis AN001032)

Values for each metabolite have been scaled by dividing by the mean across all factors

Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

MetaboliteF1F2
CerP 34:1; [M-H]-@5.97 0.7529 1.1074
CL 70:5; [M-2H](2-)@5.92 0.6699 1.1435
CL 72:3; [M-2H](2-)@7.51 0.8771 1.0534
CL 74:1; [M-2H](2-)@7.51 0.7872 1.0925
CL 74:7; [M-2H](2-)@6.12 0.7536 1.1071
CL 78:1; [M-2H](2-)@7.97 1.0754 0.9672
CL 78:9; [M-2H](2-)@6.71 0.7414 1.1124
FFA(16:0) 0.9397 1.0262
FFA(18:0) 0.9569 1.0187
FFA(18:1) 0.8533 1.0638
FFA(18:2) 0.7624 1.1033
FFA(20:0) 0.9485 1.0224
FFA(20:1) 0.7769 1.0970
FFA(20:2) 0.9233 1.0334
FFA(20:4) Arachidonic acid 0.8232 1.0768
FFA(22:0) 0.9130 1.0378
FFA(22:1) 0.7982 1.0877
FFA(22:2) 0.7475 1.1098
FFA(22:3) 0.9309 1.0301
FFA(24:0) 0.8514 1.0646
FFA(24:1) 0.7859 1.0931
FFA(24:2) 0.7848 1.0935
FFA(24:3) 0.8757 1.0540
lysoPE 16:0; [M-H]-@1.70 0.9130 1.0378
lysoPE 18:0; [M-H]-@2.47 0.7297 1.1175
lysoPE 18:1; [M-H]-@1.83 0.8827 1.0510
lysoPE 18:2; [M-H]-@1.37 0.7203 1.1216
lysoPE 20:3; [M-H]-@1.61 1.0733 0.9681
lysoPE 20:4; [M-H]-@1.33 0.9276 1.0315
lysoPE 22:4; [M-H]-@1.87 0.7238 1.1201
lysoPE 22:6; [M-H]-@1.27 0.7237 1.1201
PA 33:2; [M-H]-@1.84 0.7405 1.1128
PC 28:0; [M-Ac-H]-@5.44 0.8709 1.0561
PC 30:0; [M-Ac-H]-@6.17 1.0026 0.9989
PC 30:1; [M-Ac-H]-@5.60 1.1205 0.9476
PC 31:0; [M-Ac-H]-@6.38 0.8743 1.0546
PC 32:0; [M-Ac-H]-@6.83 1.0345 0.9850
PC 32:1; [M-Ac-H]-@6.29 1.1665 0.9276
PC 32:2; [M-Ac-H]-@5.79 0.7494 1.1090
PC 33:0; [M-Ac-H]-@7.06 1.1313 0.9429
PC 33:1; [M-Ac-H]-@6.63 0.8747 1.0545
PC 33:2; [M-Ac-H]-@6.17 0.8157 1.0801
PC 34:3; [M-Ac-H]-@5.99 0.7947 1.0892
PC 35:1; [M-Ac-H]-@7.30 1.0497 0.9784
PC 35:2; [M-Ac-H]-@6.80 0.8743 1.0547
PC 35:4; [M-Ac-H]-@6.10 0.8661 1.0582
PC 36:2; [M-Ac-H]-@7.05 0.8295 1.0741
PC 37:4; [M-Ac-H]-@6.73 0.9970 1.0013
PC 37:5; [M-Ac-H]-@6.21 0.8188 1.0788
PC 38:2; [M-Ac-H]-@7.76 0.9330 1.0291
PC 38:5; [M-Ac-H]-@6.54 0.9104 1.0390
PC 38:7; [M-Ac-H]-@5.68 0.6937 1.1332
PC 39:6; [M-Ac-H]-@6.60 0.7479 1.1096
PC 40:7; [M-Ac-H]-@6.38 0.7091 1.1265
PC 40:8; [M-Ac-H]-@5.93 0.8537 1.0636
PC 42:1; [M-Ac-H]-@9.50 0.7196 1.1219
PE 32:1; [M-H]-@6.26 1.0489 0.9787
PE 34:0; [M-H]-@6.86 0.8608 1.0605
PE 34:1; [M-H]-@6.87 0.6958 1.1323
PE 34:2; [M-H]-@6.41 0.7860 1.0931
PE 34:3; [M-H]-@6.02 0.7034 1.1290
PE 34:4; [M-H]-@5.76 0.5782 1.1834
PE 35:0; [M-H]-@7.66 0.7429 1.1118
PE 35:1; [M-H]-@7.22 0.9039 1.0418
PE 35:2; [M-H]-@6.77 0.8721 1.0556
PE 36:0; [M-H]-@7.94 0.9348 1.0283
PE 36:1; [M-H]-@7.48 0.7901 1.0912
PE 36:2; [M-H]-@6.47 0.7642 1.1025
PE 36:5; [M-H]-@6.02 0.6420 1.1557
PE 37:4; [M-H]-@6.72 0.8425 1.0685
PE 38:1; [M-H]-@7.94 1.0448 0.9805
PE 38:2; [M-H]-@7.53 0.9617 1.0166
PE 38:3; [M-H]-@7.28 1.0038 0.9984
PE 38:5; [M-H]-@6.53 0.7581 1.1052
PE 38:7; [M-H]-@6.04 0.6822 1.1382
PE 39:6; [M-H]-@6.59 0.8582 1.0616
PE 40:4; [M-H]-@7.48 0.8870 1.0491
PE 40:5; [M-H]-@7.26 0.9640 1.0156
PE 40:8; [M-H]-@6.00 0.5105 1.2128
PE 42:1; [M-H]-@9.00 0.8776 1.0532
PG 32:0; [M-H]-@5.73 1.1734 0.9246
PG 32:1; [M-H]-@5.23 1.3355 0.8541
PG 33:0; [M-H]-@6.03 1.1267 0.9449
PG 34:1; [M-H]-@5.80 1.0424 0.9816
PG 34:2; [M-H]-@5.31 0.8870 1.0491
PG 36:0; [M-H]-@6.87 1.1312 0.9429
PG 36:1; [M-H]-@6.13 1.3069 0.8666
PG 36:2; [M-H]-@6.07 0.8835 1.0506
PG 36:3; [M-H]-@5.28 0.7393 1.1134
PG 36:4; [M-H]-@4.85 0.7440 1.1113
PG 36:4; [M-H]-@5.39 0.9337 1.0288
PG 38:4; [M-H]-@6.03 0.8797 1.0523
PG 40:5; [M-H]-@6.04 1.3107 0.8649
PG 40:6; [M-H]-@5.58 1.1373 0.9403
PG 40:7; [M-H]-@5.10 0.9070 1.0404
PG 40:8; [M-H]-@4.56 0.7345 1.1154
PI 34:1; [M-H]-@5.66 0.6852 1.1369
PI 34:2; [M-H]-@5.21 0.5882 1.1790
PI 36:2; [M-H]-@5.85 0.5748 1.1849
PI 36:3; [M-H]-@5.36 0.7688 1.1005
PI 36:4; [M-H]-@5.20 0.7602 1.1043
PI 38:3; [M-H]-@6.05 0.8846 1.0502
PI 38:4; [M-H]-@5.84 0.7763 1.0972
PI 38:5; [M-H]-@5.32 0.8881 1.0486
PI 38:6; [M-H]-@5.05 0.7398 1.1131
PI 40:5; [M-H]-@5.97 0.8211 1.0778
PI 40:6; [M-H]-@5.76 0.5399 1.2001
PI 40:8; [M-H]-@4.77 0.9986 1.0006
plasmenyl-PE 32:0; [M-H]-@7.12 1.0968 0.9579
plasmenyl-PE 34:0; [M-H]-@7.28 0.9058 1.0409
plasmenyl-PE 34:3; [M-H]-@6.40 0.7842 1.0938
plasmenyl-PE 36:3; [M-H]-@6.93 0.8361 1.0712
plasmenyl-PE 36:5; [M-H]-@6.36 0.6077 1.1706
plasmenyl-PE 38:1; [M-H]-@8.31 0.7914 1.0907
plasmenyl-PE 38:2; [M-H]-@7.94 0.6478 1.1531
plasmenyl-PE 38:5; [M-H]-@6.78 0.7898 1.0914
plasmenyl-PE 40:1; [M-H]-@8.74 0.8125 1.0815
plasmenyl-PE 40:2; [M-H]-@8.34 0.6808 1.1388
plasmenyl-PE 40:3; [M-H]-@8.05 0.7671 1.1013
plasmenyl-PE 40:4; [M-H]-@7.81 0.6649 1.1457
plasmenyl-PE 40:5; [M-H]-@7.53 0.8356 1.0715
plasmenyl-PE 42:4; [M-H]-@8.28 0.8924 1.0468
plasmenyl-PE 42:5; [M-H]-@7.94 0.8153 1.0803
plasmenyl-PE 42:6; [M-H]-@7.81 0.6510 1.1518
PS 34:1; [M-H]-@5.79 0.8262 1.0756
PS 36:1; [M-H]-@6.67 0.8576 1.0619
PS 36:2; [M-H]-@5.92 0.8135 1.0811
PS 36:4; [M-H]-@5.31 1.0182 0.9921
PS 38:3; [M-H]-@6.19 1.0580 0.9748
PS 38:4; [M-H]-@5.94 0.7685 1.1007
PS 38:5; [M-H]-@5.47 0.8877 1.0488
PS 38:6; [M-H]-@5.19 0.8487 1.0658
PS 40:6; [M-H]-@5.85 0.7271 1.1186
Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

Factors:

F1Diagnosis:Control
F2Diagnosis:SIDS
  logo